PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
http://ww2.peerview.com
David M. O'Malley, MD - Immunotherapy as a Treatment Cornerstone for Advanced Endometrial Cancer: Personalizing Patient Care
Go online to PeerView.com/YTW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. What are your thoughts on the latest diagnostic guidelines and therapeutic gains for the treatment of recurrent or advanced endometrial cancer (EC)? This PeerView Live MasterClass & Practicum, based on a recent live event, showcases expert perspectives on the scientific rationale and shares practical guidance for incorporating molecular testing into the management of patients with recurrent or advanced EC. In-depth updates on efficacy and safety data for approved and emerging immunotherapeutic regimens are paired with case-based discussions of best practices for bringing individualized treatment plans to the clinic. Upon completion of this activity, participants should be better able to: Describe the rationales, therapeutic roles, and key efficacy/safety evidence of immunotherapy-based options for patients with recurrent or advanced endometrial cancer; Integrate new and emerging immunotherapy-based options into personalized treatment plans for patients with recurrent or advanced endometrial cancer, taking into consideration the latest available evidence, current guideline recommendations, and biomarker testing results; and Apply proactive, collaborative strategies to mitigate and manage immune-related adverse events in patients with recurrent and advanced endometrial cancers who are receiving novel immunotherapy-based options as part of their care.